Webpages
News Releases & Blogs
- Former Pfizer Vaccine Executive Nanette Cocero joins the PharmaJet Board of Directors.
- PharmaJet Tropis Intradermal Delivery System is Now Authorized for Two Nucleic Acid Vaccines.
- Marie Mazur Appointed Chair of PharmaJet Board of Directors
- WHO launching Polio Eradication Campaign in Pakistan using PharmaJet Precision Delivery System
- PharmaJet Announces Appointment of Nathalie Landry as Chief Scientific Officer.
- PharmaJet announces U.S. Government award expansion to clinically assess a DNA Vaccine combined with its Systems.
- Needle-Free Precision Delivery Systems boost immune response of DNA vaccines: Comprehensive scientific literature review
- PharmaJet partner Gennova Biopharmaceuticals seeks Emergency Use Authorization in India for the First Needle-free mRNA Vaccine Omicron Booster.
- PharmaJet announces clinical results from Scancell’s COVID-19 DNA vaccine study exclusively administered with their needle-free precision delivery systems.
- PharmaJet, Nigeria's National Primary Health Care Development Agency and Health-focused Consortium Launch Assessment of the PharmaJet Tropis Vaccine Delivery System
- Review highlights growing evidence that PharmaJet’s precision delivery devices improve nucleic acid vaccine performance.
- PharmaJet Tropis ID: A proven solution for intradermal (ID) delivery – overcoming the challenges made evident by the Monkeypox vaccine shortage.
- PharmaJet Partner Immunomic Therapeutics receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer
- PharmaJet Receives NIH Grant to Evaluate use of Needle-free Intradermal Delivery for HPV Immunization
- PharmaJet Needle-free System selected to deliver Intradermal Polio vaccine in Nigerian Campaign
- On World Polio Day 2022, PharmaJet announces $1.5 million grant from USAID to evaluate use of needle-free delivery in routine polio immunization
- Precision of dose and depth delivery with our needle-free jet injections is our highest priority and we have the Quality credentials to prove it.
- PharmaJet to present latest research showing superior immunogenicity with their Needle-free Systems at Five Conferences in October
- PharmaJet presents latest research showing Benefits of Needle-free at Military Health System Research Symposium
- WHO selects PharmaJet Needle-free Injection System for Million+ Polio Vaccination Campaign
- University of Adelaide begins Human Trial of Omicron COVID vaccine booster using PharmaJet Needle-free System
- PharmaJet Partner, Scancell, Announces Phase 2 Melanoma DNA Vaccine Trial will include Needle-free Delivery
- PharmaJet presents latest research showing Benefits of Needle-free at mRNA-Based Therapeutics Summit
- PharmaJet Expands Manufacturing Capacity to meet Demand for its Needle-free Injection System
- PharmaJet presents multiple partners’ data demonstrating superior immunogenicity with their Needle-free Systems at BIO International Convention
- PharmaJet Partner, Nykode Therapeutics, Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial
- The Lancet Publication Shows Benefits of PharmaJet Needle-free delivery for World’s First Commercialized Plasmid DNA COVID-19 Vaccine
- PharmaJet partner, Institute for Molecular Medicine, launches clinical trial for the first in human Alzheimer’s DNA Vaccine
- PharmaJet Announces Addition of Darin Zehrung as Chief Business Development Officer
- PharmaJet presents partner data demonstrating superior immunogenicity with their Needle-free Systems at World Vaccine Congress
- PharmaJet Launches New Interactive Website
- Video features PharmaJet Needle-free Polio Immunization Campaign
- PharmaJet partner Immunomic Therapeutics Initiates Clinical Trial of DNA Vaccine for Skin Cancer
- PharmaJet Vaccine Delivery featured at Sabin Vaccine Institute Conference
- PharmaJet partner Technovalia announces Interim results of Needle-free COVID-19 Vaccine Trial
- PharmaJet CEO featured in CEOCFO Magazine
- Healthcare Provider Preference Survey
- University of Cambridge begins COVID-19 Clinical Trial Using PharmaJet’s Needle-free System
- PharmaJet partner Zydus Cadila announces COVID-19 vaccine expansion plan to multiple countries with Korean firm
- PharmaJet partner, Nykode Therapeutics announces phase 1/2 clinical trial with next generation DNA-based COVID-19 vaccine candidates
- PharmaJet Named Asia’s Most Innovative Vaccine Delivery System at the Vaccine World Asia Congress 2021
- PharmaJet , WHO and BMGF conduct Somalia Polio Vaccination Campaign
- PharmaJet Presents Needle-free delivery of COVID-19 Vaccines and Beyond at World Vaccine Congress – Europe
- PharmaJet , WHO and BMGF conduct Somalia Polio Vaccination Campaign
- PharmaJet selected to deliver Scancell COVID-19 DNA Vaccine
- PharmaJet partner Zydus Cadila announces Emergency Use Authorization approval for world’s first plasmid DNA COVID-19 vaccine
- PharmaJet partner Zydus Cadila seeks EUA on world’s first plasmid DNA COVID-19 vaccine
- Update: PharmaJet Needle-free COVID-19 Vaccine Trial
- The Lancet Publication Confirms Viability of Intradermal Polio Vaccination
- Global NGO expands use of PharmaJet for Polio Eradication Campaigns
- PharmaJet’s Needle-free System to be used in Australian Clinical COVID-19 Trial
- PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology
- PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-free Delivery Devices
- First large-scale polio vaccination campaign using PharmaJet intradermal Needle-free Injector
- Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector
- PharmaJet and Genexine collaborate on DNA vaccine development
- Vaccibody Expands Human Clinical Trial of HPV Vaccine
- Study shows superiority of PharmaJet Needle-free Injector for poliovirus vaccine administration
- Zika Virus vaccine shows significantly higher immune response with Needle-free delivery
- Success of mRNA Rabies Vaccine Human Study linked to Needle-free Injection
- PharmaJet® partners with Serum Institute to Launch Needle-Free MMR Vaccine
- NIH Zika Vaccine Initial Trial Results Encouraging
- PharmaJet® and Vaccibody collaborate on HPV vaccine development
- PharmaJet® collaborates with World Health Organization
- NIH using PharmaJet® in DNA Vaccine Clinical Trial for Zika Virus
- Health Care Providers Report Ease of Use, and Preference for the PharmaJet Needle-Free Injector
- Survey Reveals Consumer Preference for the PharmaJet Needle-Free Flu Shot
- Patient Preference Survey
- Clinical Findings Published in The Lancet Support Administration of Flu Vaccine with PharmaJet’s Needle-Free Injector
- FDA Approves Use of Afluria®, Influenza Vaccine with PharmaJet’s Needle-Free Injector
- PharmaJet Enters into Strategic Collaboration with CureVac for Needle-Free Delivery of RNA-Based Vaccines
- PharmaJet’s Stratis® Needle-Free Injector Receives WHO PQS Certification as a Pre-qualified Delivery Device for Vaccine Administration
- PharmaJet Enters into Strategic Collaboration with CSL Limited for Needle‐free Delivery of Influenza Vaccines
- FDA Grants PharmaJet 510(k) Clearance on Intradermal Needle-Free Injection Device
- CDC Awards Contract to PharmaJet® for Development of Needle‐Free Intradermal Vaccine Delivery Device
- InnoSTARS Hot, New U.S. Medical Tech Winner Exciting Shot to Arm
- Indian Government Authorizes Needle-Free Covid Vaccine
Press Coverage
Publications
- Improved DNA Vaccine Delivery with Needle-Free Injection Systems
- A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge
- Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
- Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
- Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign
- Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
- Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice
- Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1
- Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
- Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
- Insulin-like growth factor I reduces atherosclerosis in Rapacz pigs
- Effective and Safe Stimulation of Humoral and Cell-Mediated Immunity by Intradermal Immunization with a Cyclic Dinucleotide/Nanoparticle Combination Adjuvant
- Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines
- Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
- Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
- An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan
- Development of a potent Zika virus vaccine using self-amplifying messenger RNA
- Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines
- Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models
- Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates
- Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability
- Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine
- A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
- DNA vaccination before conception protects Zika virus–exposed pregnant macaques against prolonged viremia and improves fetal outcomes
- Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies
- A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection
- Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters
- Clinical study of safety and immunogenicity of pentavalent DTP-HB-Hib vaccine administered by disposable-syringe jet injector in India
- Feasibility of jet injector use during inactivated poliovirus vaccine house-to-house vaccination campaigns
- A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate
- Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial
- Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
- Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
- Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan
- Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial
- Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination
- Rapid development of a DNA vaccine for Zika virus
- Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia
- Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates
- Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity
- Immunogenicity and safety of measles–mumps–rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: A randomized non-inferiority study
- Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: A randomized controlled trial in Cuba
- Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial
- A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates
- A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates
- Minipigs as an Animal Model for Dermal Vaccine Deliver
- A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle
- Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults
- A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18–26 years
- Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies
